Tandem Diabetes Care's Q2 2025 shows U.S. weakness, margin pressure, and rising competition, raising strategy concerns. See ...

The FDA approved the protocol update, significantly expanding patient eligibility criteria for enrollment in the study.

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Although the company's advancements have influenced contemporary healthcare, its stock presents a more cautious narrative ...

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...